

## Funding sources

Myeloma Patients Europe - 2016

Industry related outcome		
Name of company / funder	Amount of income	% of overall organisation's income
Amgen	185.597€	39,11%
BMS	100.400€	21,15%
Celgene	100.047€	21,08%
Janssen	25.000€	5,27%
Novartis	693€	0,15%
Uvet Global Business	7000€	1,48%
Apothecom Scopemedical INC	678€	0,14%
Ashfield meetings	510€	0,11%
Subtotal:	419.925€	88,49%

Non-industry related outcome		
Name of company / funder	Amount of income	% of overall organisation's income
Horizon 2020 MM Predict	36.563€	7,71%
ISPOR	1.899€	0,40%
European School of Oncology	800€	0,17%
European Medicines Agency	210€	0,04%
Withholding Tax Exemption	125€	0,03%
AEAL	15.000€	3,16%
Subtotal:	54.596€	11,51%
<b>TOTAL :</b>	<b>474.521€</b>	<b>100%</b>

Information required to be included on organisation's website	Please include links below:
Funding sources	<a href="http://www.mpeurope.org/about-mpe/sponsors/">http://www.mpeurope.org/about-mpe/sponsors/</a>
Overall proportion of industry and non-industry	
Percentage of the highest contribution from a single company	

**Comments/explanatory notes:**

Amgen: The amount 185.597€ was received by Amgen in the calendar year of 2016. However, 85.000€ of this total was received at the end of the year to fund activities taking place in 2017 (so this should not be seen as funding for 2016).